Share on StockTwits
 

OraSure Technologies (NASDAQ:OSUR) is set to release its earnings data on Wednesday, February 5th. Individual interested in registering for the company’s earnings conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.07. The company had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.21 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 11.8% on a year-over-year basis. On average, analysts expect OraSure Technologies to post $-0.39 EPS for the current fiscal year and $-0.33 EPS for the next fiscal year.

Shares of OraSure Technologies (NASDAQ:OSUR) opened at 5.53 on Tuesday. OraSure Technologies has a 52-week low of $3.75 and a 52-week high of $7.25. The stock has a 50-day moving average of $6.33 and a 200-day moving average of $5.88. The company’s market cap is $307.5 million.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of OraSure Technologies in a research note to investors on Friday, January 3rd. They now have a $9.00 price target on the stock. On a related note, analysts at Cowen and Company cut their price target on shares of OraSure Technologies from $8.00 to $7.00 in a research note to investors on Tuesday, November 26th. Finally, analysts at Cowen and Company reiterated a “buy” rating on shares of OraSure Technologies in a research note to investors on Friday, November 22nd. They now have a $8.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. OraSure Technologies presently has an average rating of “Buy” and a consensus target price of $7.92.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.